🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareMy 18-month semaglutide journey — comprehensive data log Page 4

My 18-month semaglutide journey — comprehensive data log

DataDave Sun, Jun 7, 2026 at 11:03 AM 20 replies 526 viewsPage 4 of 4
Dr.LipidDallas
VIP Member
2,678
14,567
Dec 2023
Dallas, TX
Jun 8, 2026 at 5:39 PM#16

Adding the clinical framing, because it changes how the question reads. It is worth asking what the claim would look like if it were false. If nothing would look different, it is not a claim about the world and no amount of discussion will settle it.

1 1pam_stl
Reply Quote Save Share Report
Dr.Martinez
Medical Advisor
3,891
28,456
Nov 2023
Boston, MA
Online
Jun 8, 2026 at 6:30 PM#17
Dr.LipidDallas said:
It is worth asking what the claim would look like if it were false.

Careful with the causal language. Two things moving together in a period when five things changed is not a mechanism, and stating it as one makes the thread less useful to somebody reading it later.

50 0traveltech_sara, AttorneyGrant, DebRD_ATL and 47 others
Reply Quote Save Share Report
KetoKyle
Member
678
3,456
Jul 2024
Utah
Jun 8, 2026 at 7:21 PM#18
Dr.LipidDallas said:
It is worth asking what the claim would look like if it were false.

Agreeing with Dr.LipidDallas, and the qualification matters more than the agreement. The dose-response is real but shallow at the top. Across STEP 1 and STEP 4 the gap between 1.7mg and 2.4mg is a couple of percentage points of body weight on average, and the average is carrying a wide spread — plenty of people at 1.7mg sit above the 2.4mg mean. If a dose is working and tolerable, "working" is the relevant variable, not "maximal".

Last edited: Jun 8, 2026 at 8:21 PM
49 24pat_auckland, Dr.GastroMayo, JakeBK_lifts and 46 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
adam_van
Member
212
890
Nov 2024
Vancouver, CA
Jun 8, 2026 at 8:12 PM#19
Dr.LipidDallas said:
It is worth asking what the claim would look like if it were false.

Saving this. It is the first explanation that did not require me to already understand it.

Last edited: Jun 9, 2026 at 12:12 AM
48 23tommy_boulder, hyun_seoul, jim_asheville and 45 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Jun 8, 2026 at 9:03 PM#20

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. No action needed from anybody.

26 1PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 23 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
What I wish I knew before starting GLP-1 therapy14 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register